Table of Contents

Articles

• You have access

  NEW SECONDARY METABOLITES OF PHENYLBUTYRATE IN HUMANS AND RATS

  Takhar Kasumov, Laura L. Brunengraber, Blandine Comte, Michelle A. Puchowicz, Kathryn Jobbins, Katherine Thomas, France David, Renee Kinman, Suzanne Wehrli, William Dahms, Douglas Kerr, Itzhak Nissim and Henri Brunengraber

  Drug Metabolism and Disposition January 2004, 32 (1) 10-19; DOI: https://doi.org/10.1124/dmd.32.1.10
• You have access

  SUPPRESSION OF DRUG-METABOLIZING ENZYMES AND EFFLUX TRANSPORTERS IN THE INTESTINE OF ENDOTOXIN-TREATED RATS

  J. Kalitsky-Szirtes, A. Shayeganpour, D.R. Brocks and M. Piquette-Miller

  Drug Metabolism and Disposition January 2004, 32 (1) 20-27; DOI: https://doi.org/10.1124/dmd.32.1.20
• You have access

  IN VITRO METABOLISM OF HYPERFORIN IN RAT LIVER MICROSOMAL SYSTEMS

  Yanyan Cui, Catharina Y.W. Ang, Richard D. Beger, Thomas M. Heinze, Lihong Hu and Julian Leakey

  Drug Metabolism and Disposition January 2004, 32 (1) 28-34; DOI: https://doi.org/10.1124/dmd.32.1.28
• You have access

  THE PREGNANE X RECEPTOR BINDS TO RESPONSE ELEMENTS IN A GENOMIC CONTEXT-DEPENDENT MANNER, AND PXR ACTIVATOR RIFAMPICIN SELECTIVELY ALTERS THE BINDING AMONG TARGET GENES

  Xiulong Song, Mingxing Xie, He Zhang, Yuxin Li, Karuna Sachdeva and Bingfang Yan

  Drug Metabolism and Disposition January 2004, 32 (1) 35-42; DOI: https://doi.org/10.1124/dmd.32.1.35
• You have access

  N-ACETYLATION OF THE GLUTAMATE RESIDUE OF INTACT GLUTATHIONE CONJUGATES IN RATS: A NOVEL PATHWAY FOR THE METABOLIC PROCESSING OF THIOL ADDUCTS OF XENOBIOTICS

  Wenji Yin, George A. Doss, Ralph A. Stearns and Sanjeev Kumar

  Drug Metabolism and Disposition January 2004, 32 (1) 43-48; DOI: https://doi.org/10.1124/dmd.32.1.43
• You have access

  CHARACTERIZATION OF NOVEL DIHYDROTHIENOPYRIDINIUM AND THIENOPYRIDINIUM METABOLITES OF TICLOPIDINE IN VITRO: ROLE OF PEROXIDASES, CYTOCHROMES P450, AND MONOAMINE OXIDASES

  Deepak K. Dalvie and Thomas N. O'Connell

  Drug Metabolism and Disposition January 2004, 32 (1) 49-57; DOI: https://doi.org/10.1124/dmd.32.1.49
• You have access

  METABOLISM OF APIGENIN BY RAT LIVER PHASE I AND PHASE II ENZYMES AND BY ISOLATED PERFUSED RAT LIVER

  Angéline Gradolatto, Marie-Chantal Canivenc-Lavier, Jean-Philippe Basly, Marie-Hélène Siess and Caroline Teyssier

  Drug Metabolism and Disposition January 2004, 32 (1) 58-65; DOI: https://doi.org/10.1124/dmd.32.1.58
• You have access

  CYP3A INDUCTION BY LIVER X RECEPTOR LIGANDS IN PRIMARY CULTURED RAT AND MOUSE HEPATOCYTES IS MEDIATED BY THE PREGNANE X RECEPTOR

  Sarita D. Shenoy, Thomas A. Spencer, Nancy A. Mercer-Haines, Masumeh Alipour, Mary D. Gargano, Melissa Runge-Morris and Thomas A. Kocarek

  Drug Metabolism and Disposition January 2004, 32 (1) 66-71; DOI: https://doi.org/10.1124/dmd.32.1.66
• You have access

  CHARACTERIZATION OF N-GLUCURONIDATION OF THE LUNG CARCINOGEN 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANOL (NNAL) IN HUMAN LIVER: IMPORTANCE OF UDP-GLUCURONOSYLTRANSFERASE 1A4

  Doris Wiener, Daniel R. Doerge, Jia-Long Fang, Pramod Upadhyaya and Philip Lazarus

  Drug Metabolism and Disposition January 2004, 32 (1) 72-79; DOI: https://doi.org/10.1124/dmd.32.1.72
• You have access

  THE OLIVACINE DERIVATIVE S 16020 (9-HYDROXY-5,6-DIMETHYL-N-[2-(DIMETHYLAMINO)ETHYL)-6H-PYRIDO(4,3-B)-CARBAZOLE-1-CARBOXAMIDE) INDUCES CYP1A AND ITS OWN METABOLISM IN HUMAN HEPATOCYTES IN PRIMARY CULTURE

  Lydiane Pichard-Garcia, Richard John Weaver, Nina Eckett, Graeme Scarfe, Jean-Michel Fabre, Catherine Lucas and Patrick Maurel

  Drug Metabolism and Disposition January 2004, 32 (1) 80-88; DOI: https://doi.org/10.1124/dmd.32.1.80
• You have access

  POTENT INHIBITION OF HUMAN LIVER ALDEHYDE OXIDASE BY RALOXIFENE

  R. Scott Obach

  Drug Metabolism and Disposition January 2004, 32 (1) 89-97; DOI: https://doi.org/10.1124/dmd.32.1.89
• You have access

  METABOLISM OF OPIOIDS IS ALTERED IN LIVER MICROSOMES OF SICKLE CELL TRANSGENIC MICE

  Swati Nagar, Rory P. Remmel, Robert P. Hebbel and Cheryl L. Zimmerman

  Drug Metabolism and Disposition January 2004, 32 (1) 98-104; DOI: https://doi.org/10.1124/dmd.32.1.98
• You have access

  HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE

  David M. Stresser, Marc I. Broudy, Thuy Ho, Catherine E. Cargill, Andrew P. Blanchard, Raman Sharma, Andre A. Dandeneau, Joseph J. Goodwin, Stephanie D. Turner, John C. L. Erve, Christopher J. Patten, Shangara S. Dehal and Charles L. Crespi

  Drug Metabolism and Disposition January 2004, 32 (1) 105-112; DOI: https://doi.org/10.1124/dmd.32.1.105
• You have access

  STUDIES ON THE METABOLISM OF THE NOVEL, SELECTIVE CYCLOOXYGENASE-2 INHIBITOR INDOMETHACIN PHENETHYLAMIDE IN RAT, MOUSE, AND HUMAN LIVER MICROSOMES: IDENTIFICATION OF ACTIVE METABOLITES

  Rory P. Remmel, Brenda C. Crews, Kevin R. Kozak, Amit S. Kalgutkar and Lawrence J. Marnett

  Drug Metabolism and Disposition January 2004, 32 (1) 113-122; DOI: https://doi.org/10.1124/dmd.32.1.113
• You have access

  METABOLISM AND MUTAGENICITY OF SOURCE WATER CONTAMINANTS 1,3-DICHLOROPROPANE AND 2,2-DICHLOROPROPANE

  Rogelio Tornero-Velez, Matthew K. Ross, Courtney Granville, John Laskey, Jeffrey P. Jones, David M. DeMarini and Marina V. Evans

  Drug Metabolism and Disposition January 2004, 32 (1) 123-131; DOI: https://doi.org/10.1124/dmd.32.1.123
• You have access

  DEVELOPMENT OF A COMPUTATIONAL APPROACH TO PREDICT BLOOD-BRAIN BARRIER PERMEABILITY

  Xingrong Liu, Meihua Tu, Rebecca S. Kelly, Cuiping Chen and Bill J. Smith

  Drug Metabolism and Disposition January 2004, 32 (1) 132-139; DOI: https://doi.org/10.1124/dmd.32.1.132
• You have access

  AN ASSESSMENT OF UDP-GLUCURONOSYLTRANSFERASE INDUCTION USING PRIMARY HUMAN HEPATOCYTES

  Matthew G. Soars, David M. Petullo, James A. Eckstein, Steve C. Kasper and Steven A. Wrighton

  Drug Metabolism and Disposition January 2004, 32 (1) 140-148; DOI: https://doi.org/10.1124/dmd.32.1.140
• You have access

  FUNCTIONAL CHARACTERIZATION OF FOUR NATURALLY OCCURRING VARIANTS OF HUMAN PREGNANE X RECEPTOR (PXR): ONE VARIANT CAUSES DRAMATIC LOSS OF BOTH DNA BINDING ACTIVITY AND THE TRANSACTIVATION OF THE CYP3A4 PROMOTER/ENHANCER REGION

  Satoru Koyano, Kouichi Kurose, Yoshiro Saito, Shogo Ozawa, Ryuichi Hasegawa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Toshiharu Nakajima, Kenji Matsumoto, Akira Akasawa, Hirohisa Saito and Jun-Ichi Sawada

  Drug Metabolism and Disposition January 2004, 32 (1) 149-154; DOI: https://doi.org/10.1124/dmd.32.1.149
• You have access

  TOPOLOGICAL CHANGES IN THE CYP3A4 ACTIVE SITE PROBED WITH PHENYLDIAZENE: EFFECT OF INTERACTION WITH NADPH-CYTOCHROME P450 REDUCTASE AND CYTOCHROME B₅ AND OF SITE-DIRECTED MUTAGENESIS

  Yoshitaka Yamaguchi, Kishore K. Khan, You Ai He, You Qun He and James R. Halpert

  Drug Metabolism and Disposition January 2004, 32 (1) 155-161; DOI: https://doi.org/10.1124/dmd.32.1.155